SEC Form 4 · accession 0001735276-18-000049

ALNYLAM PHARMACEUTICALS, INC. · ALNY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Michael Mason

Officer — VP, Finance and Treasurer

Period of report

Aug 10, 2018

Accepted (ET)

Aug 14, 2018 · 6:00 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001178670

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Aug 13, 2018	A	1,012	$0.00	A	1,012	D
Common Stock	Aug 13, 2018	F	449	$90.95	D	563	D
Common Stock^F2	Jan 17, 2018	J	5	$0.00	A	231	I	by Managed Account
Common Stock^F2	Apr 16, 2018	J	22	$0.00	A	253	I	by Managed Account
Common Stock^F2	Jul 10, 2018	J	23	$0.00	A	276	I	by Managed Account

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Performance Stock Option 2013 (right to buy)	$63.00	Aug 10, 2018	A	1,666	A	Aug 10, 2018	Dec 18, 2023	Common Stock	1,666	1,666	D
Performance Stock Option 2014 (right to buy)	$96.45	Aug 10, 2018	A	2,750	A	Aug 10, 2018	Dec 17, 2024	Common Stock	2,750	2,750	D

Explanation of responses

F1On January 4, 2016, the reporting person was granted a restricted stock unit (RSU) to purchase shares of ALNY common stock. The shares subject to release vest upon the commercial launch of Alnylams first internally developed product, as approved by our compensation committee. Effective August 13, 2018, the compensation committee of the Company determined the performance criterion has been met and the RSU shares have vested.
F2Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
F3On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option will vest as to the final third of the award.
F4On December 17, 2014, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by our compensation committee. Effective August 10, 2018, the compensation committee of the Company determined the final performance criteria had been met and the option vested as to the final third of the award.